Premium
Pharmacokinetic Studies of Intermediate‐ to High‐Dose 1‐β‐D‐Arabinofuranosylcytosine in Children With Acute Leukemia and Lymphoma
Author(s) -
Takashima Yoshiki,
Matsuyama Kouji
Publication year - 1987
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1987.tb03025.x
Subject(s) - nausea , vomiting , medicine , pharmacokinetics , lymphoma , cerebrospinal fluid , cytarabine , leukemia , toxicity , pharmacology , chemotherapy , acute leukemia , gastroenterology , anesthesia
Pharmacokinetic studies of intermediate and high dose 1‐β‐ d ‐arabinofuranosylcytosine (araC) therapy were performed in 14 children with acute leukemia and four with non‐Hodgkin's lymphoma (NHL). AraC administration differed by method, dosage, and time of infusion to obtain the optimal tumorcidal concentration. The toxicity of these regimens was limited to transient severe nausea and vomiting, which were tolerable. Infusion time and dose are important factors to obtain optimal and clinically effective cerebrospinal fluid (CSF) araC concentrations. A concentration of araC above 1 μg/mL in CSF, which was lethal to cells in culture, was obtained by intravenous infusion of more than 2,000 mg/m 2 of araC for four hours. We propose that araC 2,000 mg/m 2 by constant intravenous infusion is preferable in the treatment of leukemia and is associated with the fewest side effects.